Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$1.0 million.

  • Ultragenyx Pharmaceutical's Other Non Operating Income fell 13389.67% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 19916.96%. This contributed to the annual value of -$4.0 million for FY2024, which is 107596.44% down from last year.
  • Ultragenyx Pharmaceutical's Other Non Operating Income amounted to -$1.0 million in Q3 2025, which was down 13389.67% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Other Non Operating Income ranged from a high of $3.1 million in Q3 2024 and a low of -$3.6 million during Q4 2024
  • For the 5-year period, Ultragenyx Pharmaceutical's Other Non Operating Income averaged around -$295736.8, with its median value being -$415000.0 (2021).
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Other Non Operating Income crashed by 128805.97% in 2022 and then skyrocketed by 103500.0% in 2023.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Other Non Operating Income stood at -$410000.0 in 2021, then surged by 143.9% to $180000.0 in 2022, then surged by 1035.0% to $2.0 million in 2023, then plummeted by 276.51% to -$3.6 million in 2024, then skyrocketed by 71.08% to -$1.0 million in 2025.
  • Its last three reported values are -$1.0 million in Q3 2025, $2.1 million for Q2 2025, and $837000.0 during Q1 2025.